International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Robert

Kalb

,

MD

Clinical Professor Department of Dermatology
SUNY at Buffalo School of Medicine
Buffalo
,
New York
,
United States
Dr. Robert E. Kalb received his dermatology training from 1983-1986 at the College of Physicians and Surgeons at Columbia University in New York. He completed his medical internship at Cornell University/North Shore University Hospital, then served as the chief resident during his final year. He obtained his MD cum laude in 1982 from Downstate Health Science Center in Brooklyn, NY. His undergraduate degree in biochemistry summa cum laude was from the University of Buffalo. Dr. Kalb is a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences, Department of Dermatology, Buffalo, NY. He has extensive teaching responsibilities and has fourth-year medical students and residents rotating in his office on a daily basis. He is also an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Dr. Kalb has extensive experience in the research and treatment of psoriasis. He has presented numerous lectures at local, national, and international meetings. Additionally, he conducts clinical trials of new treatments for psoriasis. He is the author of 60 publications. Dr. Kalb has been in private practice with the Buffalo Medical Group (BMG) Dermatology Department since 1989. He also coordinates the Buffalo Medical Group Phototherapy Department. This serves as the principal center for psoriasis treatment in Western New York. Dr. Kalb is Board Certified by the American Board of Dermatology. He is a member of the American Academy of Dermatology, the Master’s Dermatology Society, and the Buffalo Rochester Dermatology Society.
Last Updated:
04/02/2022

Areas of Interest

Treating patients. I have a large clinical psoriasis practice, teaching of residents and medical students, participating in phase 3 clinical trials.

Languages Spoken

English